Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI01 for an undetermined period of time and are prioritizing LTI03. Our pipeline includes: LTI-03, a peptide, for...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126385 | EDGAR | 98K words |
| 2025-04-07 | 2024-12-31 | 0000950170-25-051566 | EDGAR | — |
| 2024-04-15 | 2023-12-31 | 0000950170-24-044508 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0000950170-23-008767 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004774 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001564590-21-015115 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001564590-20-014155 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001564590-19-010007 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001564590-18-007403 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281622 | EDGAR | 31K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108836 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072607 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127019 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097199 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060583 | EDGAR | — |
| 2023-10-13 | 2023-09-30 | 0000950170-23-053302 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041839 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018476 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000950170-22-020709 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017372 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007793 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-21 | 0001193125-26-310315 | EDGAR | — |
| 2026-03-02 | 0001193125-26-084012 | EDGAR | 15K words |
| 2026-02-19 | 0001193125-26-059545 | EDGAR | — |
| 2026-01-16 | 0001193125-26-015524 | EDGAR | — |
| 2025-12-11 | 0001193125-25-316225 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261706 | EDGAR | — |
| 2025-10-24 | 0001193125-25-250175 | EDGAR | — |
| 2025-10-09 | 0001193125-25-235152 | EDGAR | — |
| 2025-09-22 | 0001193125-25-210050 | EDGAR | — |
| 2025-09-09 | 0001193125-25-198816 | EDGAR | — |
161 total filings indexed. 130 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001420565 |
| Ticker | RNTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.reintx.com |
| Listed | 2017-06-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RNTX (~200 tokens, structured JSON with cryptographic provenance)